Apollo Hospitals Enterprise Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Apollo Hospitals reported strong Q1 FY26 results with consolidated revenue up 15% YoY to Rs. 5,842 crore, EBITDA up 26% to Rs. 852 crore, and PAT up 42% to Rs. 433 crore. The Healthcare Services segment grew 11% to Rs. 2,935 crore with PAT of Rs. 384 crore, while Apollo HealthCo turned profitable with PAT of Rs. 57 crore versus a loss last year. The board approved acquiring the remaining 50% stake in Apollo Gleneagles PET-CT (AGPCL) for about Rs. 85 million, making it a wholly owned subsidiary. The board also granted 327,494 stock options under ESOP 2024 at Rs. 5,258 per share and noted that the composite scheme of arrangement to demerge the pharmacy distribution and digital health business into Apollo Healthtech Limited has been filed with stock exchanges.
Strong quarterly performance with 42% PAT growth signals robust operational momentum and should be viewed positively by shareholders. The AGPCL acquisition consolidates diagnostic services, while the demerger of the digital health and pharmacy business into a separate listed entity aims to unlock value for shareholders.